Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

[Influence of FLT3-ITD Mutation and ITD Length on the Outcome on Patients with Acute Myeloid Leukemia].

Chen F, Jiang XJ, Yin CX, Zhong QX, Jiang L, Yu GP, Sun J, Meng FY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):678-683. doi: 10.7534/j.issn.1009-2137.2018.03.008. Chinese.

PMID:
29950203
2.

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1218-1226. doi: 10.1016/j.bbmt.2016.03.027. Epub 2016 Apr 4.

3.

FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

Ardestani MT, Kazemi A, Chahardouli B, Mohammadi S, Nikbakht M, Rostami S, Jalili M, Vaezi M, Alimoghaddam K, Ghavamzadeh A.

Turk J Haematol. 2018 Aug 3;35(3):158-167. doi: 10.4274/tjh.2018.0017. Epub 2018 May 22.

4.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.

Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS.

Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22.

5.

FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.

Tang S, Shen H, Mao X, Dai H, Zhu X, Xue S, Ding Z, Lu J, Wu D, Tang X.

Int J Hematol. 2017 Oct;106(4):552-561. doi: 10.1007/s12185-017-2256-7. Epub 2017 Jun 14.

PMID:
28616699
6.

[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].

Gu B, Chen GH, Shen HJ, Ma X, Fu CC, Han Y, Tang XW, Miao M, Qiu HY, Sun AN, Wu DP.

Zhonghua Nei Ke Za Zhi. 2016 Apr 1;55(4):293-7. doi: 10.3760/cma.j.issn.0578-1426.2016.04.009. Chinese.

PMID:
27030618
7.

[Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].

Yang Z, Tian H, Xu Y, Qiu H, Chen S, Sun A, Wu D.

Zhonghua Nei Ke Za Zhi. 2014 Feb;53(2):94-8. Chinese.

PMID:
24767158
8.

The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.

Qiu QC, Wang C, Bao XB, Yang J, Shen HJ, Ding ZX, Liu H, He J, Yao H, Chen SN, Li Z, Xue SL, Liu SB.

Hematology. 2018 Apr;23(3):131-138. doi: 10.1080/10245332.2017.1372248. Epub 2017 Sep 6.

PMID:
28876197
9.

Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.

Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak WW, Kyrcz-Krzemien S, Komarnicki M, Warzocha K.

Eur J Haematol. 2016 Mar;96(3):236-44. doi: 10.1111/ejh.12575. Epub 2015 May 18.

PMID:
25912052
10.

[Outcome of acute myeloid leukemia with FLT3-ITD mutation treated by allogeneic hematopoietic stem cell transplantation].

Liang C, Jiang EL, Yao JF, He Y, Zhang RL, Yang DL, Ma QL, Zhai WH, Huang Y, Wei JL, Feng SZ, Han MZ.

Zhonghua Xue Ye Xue Za Zhi. 2018 Aug 14;39(8):634-640. doi: 10.3760/cma.j.issn.0253-2727.2018.08.005. Chinese.

PMID:
30180463
11.

Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.

Fleischmann M, Schnetzke U, Schrenk KG, Schmidt V, Sayer HG, Hilgendorf I, Hochhaus A, Scholl S.

J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.

PMID:
27778197
12.

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S, Watanabe T, Taga T, Iwamoto S, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Saito AM, Kiyokawa N, Horibe K, Hara Y, Oki K, Hayashi Y, Tanaka S, Adachi S.

Int J Hematol. 2018 May;107(5):586-595. doi: 10.1007/s12185-017-2395-x. Epub 2018 Jan 12.

PMID:
29330746
13.

Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.

Ma Y, Wu Y, Shen Z, Zhang X, Zeng D, Kong P.

Clin Transplant. 2015 Feb;29(2):149-60. doi: 10.1111/ctr.12495. Epub 2015 Jan 2. Review.

PMID:
25430616
14.

Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.

PMID:
25550214
15.

[Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].

Tang SH, Lu Y, Zhang PS, Liu XH, Du XH, Chen D, Sha KY, Li SY, Cao JJ, Chen LG, Zhuang XX, Pei RZ, Tang XW.

Zhonghua Xue Ye Xue Za Zhi. 2018 Jul 14;39(7):552-557. doi: 10.3760/cma.j.issn.0253-2727.2018.07.005. Chinese.

PMID:
30122013
16.

Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis.

Huang Y, Hu J, Lu T, Luo Y, Shi J, Wu W, Han X, Zheng W, He J, Cai Z, Wei G, Huang H, Sun J.

Cancer Manag Res. 2019 May 8;11:4129-4142. doi: 10.2147/CMAR.S194523. eCollection 2019.

PMID:
31190985
17.

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V.

J Clin Oncol. 2012 Mar 1;30(7):735-41. doi: 10.1200/JCO.2011.36.9868. Epub 2012 Jan 30.

PMID:
22291086
18.

[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].

Qin T, Xu Z, Zhang Y, Lin Y, Ru K, Fang L, Zhang H, Pan L, Hu N, Qu S, Wang J, Xing R, Xiao Z.

Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):94-9. doi: 10.3760/cma.j.issn.0253-2727.2016.02.002. Chinese.

PMID:
27014976
19.

[Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].

Zhou JR, Zhang X, Zhao YL, Yang JF, Zhang JP, Cao XY, Lu Y, Liu DY, Lyu FY, Ouyang J, Lu PH.

Zhonghua Xue Ye Xue Za Zhi. 2018 Sep 14;39(9):751-756. doi: 10.3760/cma.j.issn.0253-2727.2018.09.010. Chinese.

PMID:
30369187
20.

[Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation].

Liu Y, Ke XY, Wang J, Wang JJ, Jing HM, Dong F.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Apr;26(2):354-358. doi: 10.7534/j.issn.1009-2137.2018.02.008. Chinese.

PMID:
29665898

Supplemental Content

Support Center